Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 p...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Ferrajoli, Alessandra, Lee, Bang-Ning, Schlette, Ellen J., O'Brien, Susan M., Gao, Hui, Wen, Sijin, Wierda, William G., Estrov, Zeev, Faderl, Stefan, Cohen, Evan N., Li, Changping, Reuben, James M., Keating, Michael J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2008
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082321/
https://ncbi.nlm.nih.gov/pubmed/18334676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-12-130120
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन